XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
2026-08-01 21:11
•Andy Gould •The Motley Fool
••••• •••••••• Axe Cap view
XLV or IBBQ: Stability vs. Growth in Healthcare ETFs
Choosing between broad healthcare stability and concentrated biotech growth hinges on risk tolerance and investment goals.
South African investors looking for healthcare exposure face a clear choice between steady dividends and explosive growth. XLV, with heavyweights like Lilly, Johnson & Johnson, and AbbVie, offers a lower-cost way to access large-cap pharma stability. Its 1.6% dividend yield and relatively mild drawdowns suit those who want less stress and steadier income. On the other hand, IBBQ targets biotech companies such as Vertex and Amgen, which are more sensitive to research and regulatory outcomes. The strong one-year returns are enticing but come with wild swings and a higher expense ratio. For JSE investors, Rand volatility against the USD often amplifies these moves. If your portfolio leans conservative or you rely on dividends, XLV is more fitting. If you can stomach volatility and want growth exposure, IBBQ deserves a spot. The bet on biotech’s innovation is thrilling but don’t be surprised if you hit rough patches. this is just our opinion and not financial advice
Buy XLV for broad healthcare exposure and dividend stability, but consider a small, limited position in IBBQ if your risk appetite allows. Avoid making biotech the core of your portfolio unless you have a long horizon and nerves of steel.
- XLV
- IBBQ
- USD/ZAR
- Biotech regulatory setbacks affecting IBBQ holdings
- Rand weakness amplifying USD healthcare stock volatility
6/10
XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.
Our take is based on reporting first published by The Motley Fool.